Fulcrum Therapeutics, Inc.

FULC

Fulcrum Therapeutics, Inc.

FULC

Insider Sentiment (TTM):

Last Purchase:2024-03-04Last Sale:2026-06-26Shares Purchased (TTM):0Shares Sold (TTM):4,241,591

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:70,412,882Shares Outstanding:76,215,000Institutional Ownership Pct.:92.39%

Earnings Market Reaction:

Filing Date:2026-07-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	48	50	198	47	43	42	58	73	87	40	26	30
Marketable Securities	270	283	155	154	172	184	183	185	187	173	211	227
Unbilled Receivables Current	-	-	0	0	0	1	2	4	2	0	1	1
Prepaid Expense And Other Assets Current	4	5	5	5	5	5	7	7	4	5	5	5
Assets Current	323	339	357	206	219	233	250	267	280	218	242	262
Property Plant And Equipment Net	0	2	3	3	3	4	4	4	4	5	5	6
Operating Lease Right Of Use Asset	0	4	4	5	5	5	6	6	6	7	7	8
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	0	1	1	0	0	0	0	0	2	2	2	2
Assets	324	347	366	215	229	243	261	279	294	233	258	279
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	2	2	3	2	2	1	4	4	4	3	4
Operating Lease Liability Current	3	2	2	2	2	2	2	2	2	2	2	2
Deferred Revenue Current	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities Current	10	10	13	12	9	8	11	15	13	11	14	14
Operating Lease Liability Noncurrent	3	3	4	5	5	6	6	7	8	8	9	9
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities	13	13	17	16	14	14	18	22	20	19	23	23
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	951	947	943	772	769	765	762	760	755	751	745	741
Accumulated Other Comprehensive Income Loss Net Of…	-1	-1	0	0	0	0	0	0	-0	-0	-0	-1
Retained Earnings Accumulated Deficit	-639	-613	-594	-574	-554	-537	-519	-503	-481	-537	-510	-485
Stockholders Equity	311	333	349	198	214	228	243	257	274	214	235	255
Liabilities And Stockholders Equity	324	347	366	215	229	243	261	279	294	233	258	279
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	76	67	67	54	54	54	54	54	62	62	62	62
Shares Outstanding	76	67	67	54	54	54	54	54	62	62	62	52

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-14.90%	-52.07%	-52.72%	-	-	-	-	-	-	-	-	-
2025	47.03%	59.70%	74.66%	-9.35%	-2.64%	18.45%	20.62%	31.20%	8.33%	-21.10%	-3.38%	-22.03%
2024	12.79%	-15.78%	29.93%	-1.19%	-63.79%	-62.18%	12.08%	42.70%	11.24%	-14.86%	-11.08%	85.95%
2023	-	-	-	42.73%	8.31%	-5.45%	16.32%	57.34%	62.00%	-5.01%	-32.81%	-25.83%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	31.35	34.33	27.40	17.70	24.42	28.71	22.63	18.44	22.07	20.38	17.71	18.65
Quick Ratio	30.96	33.79	27.00	17.25	23.83	28.10	22.01	17.98	21.74	19.95	17.31	18.31
Working Capital	312.55M	328.81M	344.43M	194.23M	210.39M	224.46M	238.88M	252.98M	267.59M	207.26M	228.52M	248.42M
Leverage & Debt
Debt to Equity	0.04	0.04	0.05	0.08	0.07	0.06	0.07	0.08	0.07	0.09	0.10	0.09
Interest Coverage TTM	-8.69	-8.29	-8.57	-7.84	-7.33	-1.04	-1.80	-2.43	-2.61	-8.57	-8.30	-9.27
Debt Ratio	0.04	0.04	0.05	0.08	0.06	0.06	0.07	0.08	0.07	0.08	0.09	0.08
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.34	0.31	0.29	0.27	0.01	0.01	0.01
Per Share Metrics
Diluted EPS TTM	-1.11	-1.00	-1.18	-1.14	-1.17	-0.01	-0.16	-0.29	-0.32	-1.60	-1.59	-1.60
Free Cash Flow Per Share TTM	-0.87	-0.84	-0.95	-0.97	-1.04	0.12	-0.04	-0.14	-0.20	-1.49	-1.49	-1.42
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-15.58%	-27.37%	-37.66%	-40.15%	-4,484.38%	-3,945.24%	-4,224.70%
Net Profit Margin TTM	-	-	-	-	-	-0.64%	-12.16%	-22.15%	-24.79%	-3,961.20%	-3,470.05%	-3,769.15%
Growth Metrics
Net Revenue Growth (1Y)	-	-100.00%	-100.00%	-100.00%	-100.00%	3,087.25%	2,752.05%	2,987.86%	2,582.55%	-37.95%	-55.77%	-75.56%
Net Income Growth (1Y)	16.10%	14,824.71%	669.97%	297.00%	261.84%	-99.49%	-90.01%	-81.85%	-79.44%	-8.55%	-11.41%	-7.93%
EPS Growth (1Y)	-4.79%	12,134.87%	653.31%	295.80%	259.88%	-99.49%	-90.12%	-82.02%	-79.58%	-11.89%	-34.99%	-31.18%
Valuation Metrics
P/E TTM	-3.28	-7.68	-9.57	-8.10	-5.88	-352.82	-29.96	-12.44	-19.06	-5.89	-4.25	-2.78
P/B TTM	0.90	1.75	2.05	2.90	2.01	0.79	1.20	0.87	1.41	2.74	1.76	1.07
P/S TTM	-	-	-	-	-	2.25	3.64	2.76	4.72	233.12	147.54	104.81
Market Cap	279.13M	584.57M	716.55M	575.89M	430.30M	179.94M	291.32M	222.80M	385.67M	585.13M	413.84M	274.49M
Enterprise Value	230.66M	534.31M	650.86M	528.81M	387.71M	137.76M	233.11M	150.17M	298.97M	545.18M	388.28M	244.41M
Calculated Values
Free Cash Flow TTM	-66.14M	-63.88M	-60.38M	-60.41M	-65.23M	7.56M	-2.50M	-8.74M	-12.62M	-92.50M	-91.47M	-88.05M
Net Debt	-48.47M	-50.26M	-65.69M	-47.08M	-42.59M	-42.18M	-58.21M	-72.63M	-86.70M	-39.95M	-25.56M	-30.08M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-26Sale

Owner: Ezekowitz, Alan

Title: -

Shares: 18,000

Price/Share: $3.65

Value: $65,700.00

Shares Owned: 10,927

Relationship: Director

Ownership: Direct

2026-02-02Sale

Owner: Gould, Robert J

Title: -

Shares: 15,000

Price/Share: $10.72

Value: $160,800.00

Shares Owned: 454,864

Relationship: Director

Ownership: Direct

2026-01-02Sale

Owner: Gould, Robert J

Title: -

Shares: 15,000

Price/Share: $10.87

Value: $163,050.00

Shares Owned: 469,864

Relationship: Director

Ownership: Direct

2025-12-15Sale

Owner: Oltmans, Curtis Gale

Title: Chief Legal Officer

Shares: 3,452

Price/Share: $12.92

Value: $44,599.84

Shares Owned: 10,252

Relationship: Officer

Ownership: Direct

2025-12-08Sale

Owner: Ra, Capital Healthcare Fu…

Title: -

Shares: 4,175,139

Price/Share: $14.20

Value: $59,286,973.80

Shares Owned: 6,053,960

Relationship: TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-26	Ezekowitz, Alan	Director	-	Direct	Sale	18,000	3.65	$65,700.00	10,927	4
2026-02-02	Gould, Robert J	Director	-	Direct	Sale	15,000	10.72	$160,800.00	454,864	4
2026-01-02	Gould, Robert J	Director	-	Direct	Sale	15,000	10.87	$163,050.00	469,864	4/A
2025-12-15	Oltmans, Curtis Gale	Officer	Chief Legal Officer	Direct	Sale	3,452	12.92	$44,599.84	10,252	4
2025-12-08	Ra, Capital Healthcare Fu…	TenPercentOwner	-	Indirect	Sale	4,175,139	14.20	$59,286,973.80	6,053,960	4
2025-11-19	Gould, Robert J	Director	-	Direct	Sale	15,000	11.03	$165,450.00	484,864	4
2025-05-08	Tourangeau, Greg	Officer	Principal Accounting Officer	Direct	Sale	498	5.06	$2,519.88	14,062	4
2024-05-07	Tourangeau, Greg	Officer	Principal Accounting Officer	Direct	Sale	236	7.76	$1,831.36	11,571	4
2024-03-08	Tourangeau, Greg	Officer	Vice President, Finance	Direct	Sale	4,884	11.72	$57,240.48	11,807	4
2024-03-04	Sapir, Alex	Director,Officer	See Remarks	Direct	Purchase	43,360	11.35	$492,136.00	43,360	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

92.39%

Inst. Shares: 70,412,882

Shares Outstanding: 76,215,000

2025-12-31

104.40%

Inst. Shares: 66,141,879

Shares Outstanding: 63,355,000

2025-09-30

83.92%

Inst. Shares: 52,530,071

Shares Outstanding: 62,597,000

2025-06-30

84.85%

Inst. Shares: 53,070,582

Shares Outstanding: 62,544,000

2025-03-31

80.49%

Inst. Shares: 50,291,944

Shares Outstanding: 62,479,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	70,412,882	76,215,000	92.39%
2025-12-31	66,141,879	63,355,000	104.40%
2025-09-30	52,530,071	62,597,000	83.92%
2025-06-30	53,070,582	62,544,000	84.85%
2025-03-31	50,291,944	62,479,000	80.49%
2024-12-31	50,832,148	61,984,000	82.01%
2024-09-30	53,831,371	62,409,000	86.26%
2024-06-30	63,877,035	62,205,000	102.69%
2024-03-31	59,620,867	61,984,000	96.19%
2023-12-31	56,988,928	61,310,000	92.95%
2023-09-30	55,811,988	61,823,000	90.28%
2023-06-30	54,362,167	61,794,000	87.97%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Fulcrum Therapeutics, Inc. (FULC) — SEC Financial Statements & Analysis

Fulcrum Therapeutics, Inc. (FULC) is a pharmaceutical preparations company, incorporated in DE. Fulcrum Therapeutics, Inc. trades on Nasdaq as: FULC. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Fulcrum Therapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.04x, a Price-to-Sales (P/S) ratio of 2.25x (TTM), a Price-to-Book (P/B) ratio of 0.90x (TTM), at a market cap of $279.13M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.04x
P/S TTM: 2.25x
P/B TTM: 0.90x
Market Cap: $279.13M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Fulcrum Therapeutics, Inc. in?

Fulcrum Therapeutics, Inc. (FULC) operates in the Pharmaceutical Preparations industry.

What is FULC's market cap?

Fulcrum Therapeutics, Inc. (FULC) has a market capitalization of $279.13M as of 2026-06-30.

What exchange does FULC trade on?

Fulcrum Therapeutics, Inc. (FULC) trades on the Nasdaq.

Where is Fulcrum Therapeutics, Inc. incorporated?

Fulcrum Therapeutics, Inc. is incorporated in DE.